24. Fibroblast Growth Factor-23 (FGF23)

  1. Clifford J. Rosen MD
  1. Kenneth E. White and
  2. Michael J. Econs

Published Online: 19 JUL 2013

DOI: 10.1002/9781118453926.ch24

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

How to Cite

White, K. E. and Econs, M. J. (2013) Fibroblast Growth Factor-23 (FGF23), in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition (ed C. J. Rosen), John Wiley & Sons, Inc., Ames, USA. doi: 10.1002/9781118453926.ch24

Publication History

  1. Published Online: 19 JUL 2013

ISBN Information

Print ISBN: 9781118453889

Online ISBN: 9781118453926

SEARCH

Keywords:

  • autosomal dominant hypophosphatemic rickets (ADHR);
  • autosomal recessive hypophosphatemic rickets;
  • chronic kidney disease (CKD);
  • familial tumoral calcinosis;
  • fibroblast growth factor-23 (FGF23);
  • serum assays;
  • tumor-induced osteomalacia (TIO);
  • X-linked hypophosphatemic rickets (XLH)

Summary

The Fibroblast Growth Factor-23 (FGF23) gene resides on human chromosome 12p13 (mouse chromosome 6). It comprises three coding exons and contains an open reading frame of 251 residues. FGF23 has overlapping function with PTH to reduce renal Pi reabsorption, but it has the opposite effects on 1,25(OH)2D. FGF23 is measured in the circulation via several assays. One extensively used assay is a “C-terminal” FGF23 ELISA with both the capture and detection antibodies binding the C-terminal to the FGF23 176RXXR179/S cleavage site. This assay thus recognizes full-length FGF23 as well as C-terminal proteolytic fragments. This chapter discusses the disorders associated with both increased and reduced FGF23 bioactivity. Some of these disorders include autosomal dominant hypophosphatemic rickets (ADHR), tumor-induced osteomalacia (TIO), X-linked hypophosphatemic rickets (XLH), autosomal recessive hypophosphatemic rickets types 1 and 2, familial tumoral calcinosis, and chronic kidney disease (CKD).